ARVINAS INC (ARVN)
US04335A1051 - Common Stock
Arvinas (ARVN) Shares Cross Below 200 DMA
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under...
Arvinas is Now Oversold (ARVN)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
Arvinas to Participate in Upcoming Investor Conferences
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of $43.1M misses by $92.4M (NASDAQ:ARVN)
Arvinas reports Q4 financial results, missing on GAAP EPS by $1.38 and revenue by $92.4M.
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2...
Arvinas announces CFO Sean Cassidy's departure (NASDAQ:ARVN)
Arvinas announces CFO departure and launches search for replacement. Randy Teel to serve as interim CFO.
Arvinas Announces Chief Financial Officer Transition
Arvinas Announces Chief Financial Officer Transition
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn.,...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase...
Citi downgrades Arvinas to neutral, cites valuation (NASDAQ:ARVN)
Citi has downgraded Arvinas (ARVN) to neutral, citing valuation following a recent run-up in the stock. Read more here.
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Arvinas stock rises on fast track status for breast cancer candidate with Pfizer
Arvinas receives fast track designation from FDA for breast cancer therapy, boosting shares by 2%.
Pfizer, Arvinas' breast cancer therapy gets FDA fast track status (NASDAQ:ARVN)
Arvinas receives fast track designation from FDA for breast cancer therapy, boosting shares by 2%.
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER)...
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas stock draws Buy at Goldman Sachs on breast cancer drug
Goldman Sachs initiates coverage on Arvinas (ARVN) with a Buy rating and $70 target citing its breast cancer therapy vepdegestrant. Read more here.
Arvinas Appoints Jared Freedberg as General Counsel
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)
Arvinas Appoints Jared Freedberg as General Counsel
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)...
Wells Fargo upgrades Arvinas to overweight ahead of Phase 3 data readout (NASDAQ:ARVN)
Wells Fargo has upgraded Arvinas (ARVN) to overweight ahead of an expected readout of Phase 3 data for the company’s oncology drug vepdegestran, which is expect